Diffusion MRI phenotypes predict overall survival benefit from anti-VEGF monotherapy in recurrent glioblastoma: Converging evidence from phase II trials

PURPOSE: Anti-VEGF therapies remain controversial in the treatment of recurrent glioblastoma (GBM). In the current study we demonstrate that recurrent GBM patients with a specific diffusion MR imaging signature have an overall survival (OS) advantage when treated with cediranib, bevacizumab, cabozan...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Cancer Res
Autori principali: Ellingson, Benjamin M., Gerstner, Elizabeth R., Smits, Marion, Huang, Raymond Y., Colen, Rivka, Abrey, Lauren E., Aftab, Dana T., Schwab, Gisela M., Hessel, Colin, Harris, Robert J., Chakhoyan, Ararat, Gahrmann, Renske, Pope, Whitney B., Leu, Kevin, Raymond, Catalina, Woodworth, Davis C., de Groot, John, Wen, Patrick Y., Batchelor, Tracy T., van den Bent, Martin J., Cloughesy, Timothy F.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5626594/
https://ncbi.nlm.nih.gov/pubmed/28655794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-2844
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi